The recently published ERCC1-trial (ET) was the largest prospective randomised phase-III study in advanced NSCLC specifically designed to evaluate prospective testing of ERCC1 in the tumour tissue with immunohistochemistry assay, as predictive biomarker of platinum-based chemotherapy.10 ET failed to demonstrate any predictive role of the ERCC1 test evaluated either alone or in combination with the XPF assay. Here, ERCC1 is linked to neoplasm.